Apolipoprotein C-II is a Potential Serum Biomarker as a Prognostic Factor of Patients With Locally Advanced Cervical Cancer After Chemoradiation Therapy

Abstract

Listen

Translate article

Purpose/Objective(s)To determine the usefulness of pretreatment serum protein level as a generally applicable measurement in predicting and estimating the chemoradiation treatment outcome of patients with locally advanced squamous cell cervical carcinoma (CC).Materials/MethodsIn our previous study, the peptide 8,918 m/z peak was identified by surface-enhanced laser desorption and ionization-time-of-flight mass spectrometry (SELDI-TOF MS) in predicting the chemoradiation treatment outcome of 46 patients with CC. Subsequently, the protein that best matches this peptide 8,918 m/z peak was identified as Apolipoprotein C-II (ApoC-II) using PMF and MS/MS methods. In this series, a total of 65 patients with CC who underwent definitive chemoradiation therapy between January 2003 and October 2009 were included. Age, tumor size, stage, HPV status, and pretreatment serum values of SCC, ApoC-II, MMP1, and MMP2 of 35 patients in the good prognosis group and 30 in the poor one were compared. The endpoint was the correlations between the patient characteristics and cause-specific survival rate as determined by univariate and multivariate Cox proportional-hazard model analysis.ResultsApoC-II levels in the poor prognosis group were significantly lower than those in the good one (p = 0.03). On univariate and multivariate analysis, ApoC-II was a significant independent predictor of poor cause-specific survival rate (p = 0.01, p = 0.02). The specificity and sensitivity of ApoC-II levels were 97.9% and 44.4%, respectively, as determined using ROC curves.ConclusionsApoC-II level correlated with outcome in patients with CC after radiation therapy. ApoC-II could be used as a biomarker for detection in predicting and estimating the radiation treatment outcome of patients with CC. Purpose/Objective(s)To determine the usefulness of pretreatment serum protein level as a generally applicable measurement in predicting and estimating the chemoradiation treatment outcome of patients with locally advanced squamous cell cervical carcinoma (CC). To determine the usefulness of pretreatment serum protein level as a generally applicable measurement in predicting and estimating the chemoradiation treatment outcome of patients with locally advanced squamous cell cervical carcinoma (CC). Materials/MethodsIn our previous study, the peptide 8,918 m/z peak was identified by surface-enhanced laser desorption and ionization-time-of-flight mass spectrometry (SELDI-TOF MS) in predicting the chemoradiation treatment outcome of 46 patients with CC. Subsequently, the protein that best matches this peptide 8,918 m/z peak was identified as Apolipoprotein C-II (ApoC-II) using PMF and MS/MS methods. In this series, a total of 65 patients with CC who underwent definitive chemoradiation therapy between January 2003 and October 2009 were included. Age, tumor size, stage, HPV status, and pretreatment serum values of SCC, ApoC-II, MMP1, and MMP2 of 35 patients in the good prognosis group and 30 in the poor one were compared. The endpoint was the correlations between the patient characteristics and cause-specific survival rate as determined by univariate and multivariate Cox proportional-hazard model analysis. In our previous study, the peptide 8,918 m/z peak was identified by surface-enhanced laser desorption and ionization-time-of-flight mass spectrometry (SELDI-TOF MS) in predicting the chemoradiation treatment outcome of 46 patients with CC. Subsequently, the protein that best matches this peptide 8,918 m/z peak was identified as Apolipoprotein C-II (ApoC-II) using PMF and MS/MS methods. In this series, a total of 65 patients with CC who underwent definitive chemoradiation therapy between January 2003 and October 2009 were included. Age, tumor size, stage, HPV status, and pretreatment serum values of SCC, ApoC-II, MMP1, and MMP2 of 35 patients in the good prognosis group and 30 in the poor one were compared. The endpoint was the correlations between the patient characteristics and cause-specific survival rate as determined by univariate and multivariate Cox proportional-hazard model analysis. ResultsApoC-II levels in the poor prognosis group were significantly lower than those in the good one (p = 0.03). On univariate and multivariate analysis, ApoC-II was a significant independent predictor of poor cause-specific survival rate (p = 0.01, p = 0.02). The specificity and sensitivity of ApoC-II levels were 97.9% and 44.4%, respectively, as determined using ROC curves. ApoC-II levels in the poor prognosis group were significantly lower than those in the good one (p = 0.03). On univariate and multivariate analysis, ApoC-II was a significant independent predictor of poor cause-specific survival rate (p = 0.01, p = 0.02). The specificity and sensitivity of ApoC-II levels were 97.9% and 44.4%, respectively, as determined using ROC curves. ConclusionsApoC-II level correlated with outcome in patients with CC after radiation therapy. ApoC-II could be used as a biomarker for detection in predicting and estimating the radiation treatment outcome of patients with CC. ApoC-II level correlated with outcome in patients with CC after radiation therapy. ApoC-II could be used as a biomarker for detection in predicting and estimating the radiation treatment outcome of patients with CC.